Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat versus best available therapy for essential thrombocythemia after hydroxyurea failure or intolerance
NL-OMON59171Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bomedemstat in thrombocythemia (2 arms), sponsored by Merck & Co. Primary endpoint: Durable Clinicohematologic Response Rate. Started May 2024; status: active, not recruiting.
02
Drugs
bomedemstat
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on NL-OMON59171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59171.